{"count": 7, "results": [{"_id": "33232759", "pmid": 33232759, "title": "Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.", "journal": "Diabetes Res Clin Pract", "authors": ["Wu CY", "Wu CY", "Li CP", "Chou YJ", "Lin YH", "Chang YT"], "date": "2021-01-01T00:00:00Z", "doi": "10.1016/j.diabres.2020.108546", "meta_date_publication": "2021 Jan", "meta_volume": "171", "meta_issue": "", "meta_pages": "108546", "score": 50254.035, "text_hl": "Modified Cox regression analysis revealed that DPP4i treatment (HR: 2.15, 95% CI: 1.18-3.91, P = 0.01), age (HR: 1.06, P < 0.001), @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@renal disease@@@ (HR: 2.32, P < 0.001), and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ user (HR: 1.93, P = 0.006) were associated with increased @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@BP@@@ risk. ", "citations": {"NLM": "Wu CY, Wu CY, Li CP, Chou YJ, Lin YH, Chang YT. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. Diabetes Res Clin Pract. 2021 Jan;171():108546. PMID: 33232759", "BibTeX": "@article{33232759, title={Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study.}, author={Wu CY and Wu CY and Li CP and Chou YJ and Lin YH and Chang YT}, journal={Diabetes Res Clin Pract}, volume={171}, pages={108546}}"}}, {"_id": "40927818", "pmid": 40927818, "title": "Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports.", "journal": "Cutan Ocul Toxicol", "authors": ["Mahesh R", "Das K A", "Thomas C", "Kotakonda SR", "Maheshwari K", "Undela K"], "date": "2025-09-10T00:00:00Z", "doi": "10.1080/15569527.2025.2554799", "meta_date_publication": "2025 Sep 10", "meta_volume": "", "meta_issue": "", "meta_pages": "1-33", "score": 50253.07, "text_hl": "RESULTS: Disproportionality analysis identified 61 signals, and the following drugs exhibited the highest number of @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@BP@@@ case associations: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (596 cases), @CHEMICAL_Vildagliptin @CHEMICAL_MESH:D000077597 @@@vildagliptin@@@ (406 cases), @CHEMICAL_Nivolumab @CHEMICAL_MESH:D000077594 @@@nivolumab@@@ (376 cases), and @CHEMICAL_Furosemide @CHEMICAL_MESH:D005665 @@@furosemide@@@ (301 cases). ", "citations": {"NLM": "Mahesh R, Das K A, Thomas C, Kotakonda SR, Maheshwari K, Undela K. Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports. Cutan Ocul Toxicol. 2025 Sep 10;():1-33. PMID: 40927818", "BibTeX": "@article{40927818, title={Identifying potential drug triggers for bullous pemphigoid: a disproportionality analysis of the FDA adverse event reporting system and systematic review of case reports.}, author={Mahesh R and Das K A and Thomas C and Kotakonda SR and Maheshwari K and Undela K}, journal={Cutan Ocul Toxicol}, pages={1-33}}"}}, {"_id": "23437788", "pmid": 23437788, "title": "Metformin in dermatology: an overview.", "journal": "J Eur Acad Dermatol Venereol", "authors": ["Badr D", "Kurban M", "Abbas O"], "date": "2013-11-01T00:00:00Z", "doi": "10.1111/jdv.12116", "meta_date_publication": "2013 Nov", "meta_volume": "27", "meta_issue": "11", "meta_pages": "1329-35", "score": 50068.082, "text_hl": "In addition, cutaneous side-effects such as @DISEASE_Erythema_elevatum_diutinum @DISEASE_MESH:C535509 @@@leukocytoclastic vasculitis@@@, @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@bullous pemphigoid@@@, @DISEASE_Drug_Eruptions @DISEASE_MESH:D003875 @@@psoriasiform drug eruption@@@, @DISEASE_Lichen_Planus @DISEASE_MESH:D008010 @@@lichen planus@@@ and acute @DISEASE_Alopecia @DISEASE_MESH:D000505 @@@alopecia@@@ have been associated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use and are discussed in the article. ", "citations": {"NLM": "Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1329-35. PMID: 23437788", "BibTeX": "@article{23437788, title={Metformin in dermatology: an overview.}, author={Badr D and Kurban M and Abbas O}, journal={J Eur Acad Dermatol Venereol}, volume={27}, number={11}, pages={1329-35}}"}}, {"_id": "24861252", "pmid": 24861252, "title": "Bullous pemphigoid induced by vildagliptin: a report of three cases.", "journal": "Fundam Clin Pharmacol", "authors": ["Béné J", "Jacobsoone A", "Coupe P", "Auffret M", "Babai S", "Hillaire-Buys D", "Jean-Pastor MJ", "Vonarx M", "Vermersch A", "Tronquoy AF", "Gautier S"], "date": "2015-02-01T00:00:00Z", "doi": "10.1111/fcp.12083", "meta_date_publication": "2015 Feb", "meta_volume": "29", "meta_issue": "1", "meta_pages": "112-4", "score": 50067.652, "text_hl": "Case 1: An 86-year-old @SPECIES_9606 @@@woman@@@ presented with @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@bullous pemphigoid@@@ after 1 month of treatment with @CHEMICAL_Vildagliptin @CHEMICAL_MESH:D000077597 @@@vildagliptin@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Béné J, Jacobsoone A, Coupe P, Auffret M, Babai S, Hillaire-Buys D, Jean-Pastor MJ, Vonarx M, Vermersch A, Tronquoy AF, Gautier S. Bullous pemphigoid induced by vildagliptin: a report of three cases. Fundam Clin Pharmacol. 2015 Feb;29(1):112-4. PMID: 24861252", "BibTeX": "@article{24861252, title={Bullous pemphigoid induced by vildagliptin: a report of three cases.}, author={Béné J and Jacobsoone A and Coupe P and Auffret M and Babai S and Hillaire-Buys D and Jean-Pastor MJ and Vonarx M and Vermersch A and Tronquoy AF and Gautier S}, journal={Fundam Clin Pharmacol}, volume={29}, number={1}, pages={112-4}}"}}, {"_id": "21466592", "pmid": 21466592, "title": "Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.", "journal": "J Eur Acad Dermatol Venereol", "authors": ["Skandalis K", "Spirova M", "Gaitanis G", "Tsartsarakis A", "Bassukas ID"], "date": "2012-02-01T00:00:00Z", "doi": "10.1111/j.1468-3083.2011.04062.x", "meta_date_publication": "2012 Feb", "meta_volume": "26", "meta_issue": "2", "meta_pages": "249-53", "score": 50065.2, "text_hl": "Five of them were on gliptin plus @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (three different trade preparations) for 2-13 months prior to @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@BP@@@ onset. ", "citations": {"NLM": "Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012 Feb;26(2):249-53. PMID: 21466592", "BibTeX": "@article{21466592, title={Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.}, author={Skandalis K and Spirova M and Gaitanis G and Tsartsarakis A and Bassukas ID}, journal={J Eur Acad Dermatol Venereol}, volume={26}, number={2}, pages={249-53}}"}}, {"_id": "27191539", "pmid": 27191539, "title": "Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.", "journal": "J Clin Pharm Ther", "authors": ["García M", "Aranburu MA", "Palacios-Zabalza I", "Lertxundi U", "Aguirre C"], "date": "2016-06-01T00:00:00Z", "doi": "10.1111/jcpt.12397", "meta_date_publication": "2016 Jun", "meta_volume": "41", "meta_issue": "3", "meta_pages": "368-370", "score": 50062.375, "text_hl": "CASE SUMMARY: A 74-year-old @SPECIES_9606 @@@woman@@@, treated with @CHEMICAL_Vildagliptin @CHEMICAL_MESH:D000077597 @@@vildagliptin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for 12 months, developed @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@bullous pemphigoid@@@, confirmed by skin biopsy. ", "citations": {"NLM": "García M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2016 Jun;41(3):368-370. PMID: 27191539", "BibTeX": "@article{27191539, title={Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.}, author={García M and Aranburu MA and Palacios-Zabalza I and Lertxundi U and Aguirre C}, journal={J Clin Pharm Ther}, volume={41}, number={3}, pages={368-370}}"}}, {"_id": "28856675", "pmid": 28856675, "title": "Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center.", "journal": "Int J Dermatol", "authors": ["Kremer N", "Zeeli T", "Sprecher E", "Geller S"], "date": "2017-10-01T00:00:00Z", "doi": "10.1111/ijd.13736", "meta_date_publication": "2017 Oct", "meta_volume": "56", "meta_issue": "10", "meta_pages": "1010-1016", "score": 50058.76, "text_hl": "@DISEASE_Hypertension @DISEASE_MESH:D006973 @@@Hypertension@@@, head involvement, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ therapy were found to be significantly associated with the need for adjuvant therapy to achieve initial control, suggesting that these parameters may serve as predictors of treatment response in @<m>DISEASE_Pemphigoid_Bullous</m> @DISEASE_MESH:D010391 @@@BP@@@.", "citations": {"NLM": "Kremer N, Zeeli T, Sprecher E, Geller S. Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center. Int J Dermatol. 2017 Oct;56(10):1010-1016. PMID: 28856675", "BibTeX": "@article{28856675, title={Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center.}, author={Kremer N and Zeeli T and Sprecher E and Geller S}, journal={Int J Dermatol}, volume={56}, number={10}, pages={1010-1016}}"}}]}